Literature DB >> 9224643

Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein.

C Haas1, P Cazorla, C D Miguel, F Valdivieso, J Vázquez.   

Abstract

Apolipoprotein E (apoE), a protein genetically linked to the incidence of Alzheimer's disease, forms SDS-stable complexes in vitro with beta-amyloid peptide (Abeta), the primary component of senile plaques. In the present study, we investigated whether apoE was able to bind full-length Abeta precursor protein (APP). Using a maltose-binding-protein-APP fusion protein and human very-low-density lipoprotein (VLDL), we detected an interaction of apoE with APP that was inhibited by Abeta or anti-apoE antibody. Saturation-binding experiments indicated a single binding equilibrium with an apparent 1:1 stoichiometry and a dissociation constant of 15 nM. An interaction was also observed using apoE from cerebrospinal fluid or delipidated VLDL, as well as recombinant apoE. APP.apoE complexes were SDS-stable, and their formation was not inhibited by reducing conditions; however, they were dissociated by SDS under reducing conditions. ApoE.APP complexes formed high-molecular-mass aggregates, and competition experiments suggested that amino acids 14-23 of Abeta are responsible for complex-formation. Finally, no differences were found when studying the interaction of APP with apoE3 or apoE4. Taken together, our results demonstrate that apoE may form stable complexes with the Abeta moiety of APP with characteristics similar to those of complexes formed with isolated Abeta, and suggest the intriguing possibility that apoE-APP interactions may be pathologically relevant in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9224643      PMCID: PMC1218542          DOI: 10.1042/bj3250169

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

2.  Isolation and characterization of apolipoprotein E.

Authors:  S C Rall; K H Weisgraber; R W Mahley
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

3.  Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins.

Authors:  R E Pitas; J K Boyles; S H Lee; D Foss; R W Mahley
Journal:  Biochim Biophys Acta       Date:  1987-01-13

4.  Arrest of beta-amyloid fibril formation by a pentapeptide ligand.

Authors:  L O Tjernberg; J Näslund; F Lindqvist; J Johansson; A R Karlström; J Thyberg; L Terenius; C Nordstedt
Journal:  J Biol Chem       Date:  1996-04-12       Impact factor: 5.157

5.  Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain.

Authors:  R E Pitas; J K Boyles; S H Lee; D Hui; K H Weisgraber
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

6.  Tables for estimating sedimentation through linear concentration gradients of sucrose solution.

Authors:  C R McEwen
Journal:  Anal Biochem       Date:  1967-07       Impact factor: 3.365

7.  Nerve injury stimulates the secretion of apolipoprotein E by nonneuronal cells.

Authors:  G J Snipes; C B McGuire; J J Norden; J A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

Review 8.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.

Authors:  R W Mahley
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

9.  A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve.

Authors:  J K Boyles; C D Zoellner; L J Anderson; L M Kosik; R E Pitas; K H Weisgraber; D Y Hui; R W Mahley; P J Gebicke-Haerter; M J Ignatius
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

10.  Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system.

Authors:  J K Boyles; R E Pitas; E Wilson; R W Mahley; J M Taylor
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

View more
  6 in total

1.  ApoE and cholesterol in schizophrenia and bipolar disorder: comparison of grey and white matter and relation with APOE genotype.

Authors:  Fidel Vila-Rodriguez; William G Honer; Sheila M Innis; Cheryl L Wellington; Clare L Beasley
Journal:  J Psychiatry Neurosci       Date:  2011-01       Impact factor: 6.186

2.  Structural and functional alterations in amyloid-β precursor protein induced by amyloid-β peptides.

Authors:  Clare Peters Libeu; Karen S Poksay; Varghese John; Dale E Bredesen
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Insertion of the amyloid precursor protein into lipid monolayers: effects of cholesterol and apolipoprotein E.

Authors:  Raghda Lahdo; Laurence De La Fournière-Bessueille
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

4.  Neuroprotective Sirtuin ratio reversed by ApoE4.

Authors:  Veena Theendakara; Alexander Patent; Clare A Peters Libeu; Brittany Philpot; Sonia Flores; Olivier Descamps; Karen S Poksay; Qiang Zhang; Gabriellee Cailing; Matthew Hart; Varghese John; Rammohan V Rao; Dale E Bredesen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

5.  Altering APP proteolysis: increasing sAPPalpha production by targeting dimerization of the APP ectodomain.

Authors:  Clare A Peters Libeu; Olivier Descamps; Qiang Zhang; Varghese John; Dale E Bredesen
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

6.  Brain cell apoptosis inhibition by butylphthalide in Alzheimer's disease model in rats.

Authors:  Fu-Xia Song; Li Wang; Hong Liu; Ying-Li Wang; Yong Zou
Journal:  Exp Ther Med       Date:  2017-04-10       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.